Palisade Bio (PALI) Stock Overview

A clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. More details

PALI fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market

PALI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Palisade Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Palisade Bio
Historical stock prices
Current Share Price	US$1.81
52 Week High	US$2.86
52 Week Low	US$0.53
Beta	1.53
1 Month Change	-12.14%
3 Month Change	4.62%
1 Year Change	166.14%
3 Year Change	-92.31%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Dec 23

Palisade Bio: Gut Prodrug For IBD With Catalysts

Summary Palisade Bio’s bull thesis centers on PALI-2108. This is a gut-targeted PDE4 prodrug aiming for local efficacy with fewer systemic PDE4 side effects. The main target indications are UC and FSCD, which promise a sizable TAM if PALI-2108 ultimately succeeds. Naturally, this means PALI’s story remains early-stage and highly data-dependent. Yet, they have a compelling near-term catalyst stack. PALI’s recent October 2025 raise also materially improved their cash runway and liquidity. Using those numbers, its valuation looks compelling relative to its peers. Thus, I lean towards a speculative "Buy" rating on PALI. Read the full article on Seeking Alpha

Seeking Alpha • Oct 11

Palisade Bio announces CEO transition

Palisade Bio (NASDAQ:PALI) announced an executive leadership transition effective October 10, 2022, Thomas Hallam, Ph.D., ceased his duties as CEO. The company’s board of directors has appointed JD Finley, current CFO, as interim CEO, and Mr. Finley has assumed the duties of Dr. Hallam effective October 10, 2022. Prior to joining Palisade Bio, Mr. Finley was the CEO, president and CFO for PointAcross, a software company providing business messaging and communications services.

Seeking Alpha • Sep 15

Palisade Bio streamlines operations, including cutting 20% of employees

Palisade Bio (NASDAQ:PALI) is undergoing a program to streamline operations that includes focusing on lead clinical program LB1148 and laying off 20% of its staff. The gastrointestinal-focused biotech said it is implementing cost-savings measures of more than $1.5M per year. LB1148, a broad-spectrum serine protease inhibitor, is in phase 3 for GI surgery and phase 2 for cardiovascular surgery, both in terms of accelerating return of postoperative GI function. It is also in phase 2 in GI surgery for prevention of post-surgical abdominal adhesions. Seeking Alpha's Quant Rating views Palisade Bio (PALI) as a hold with high marks for valuation, profitability, and revisions.

Seeking Alpha • Aug 15

Palisade Bio GAAP EPS of -$0.12

Palisade Bio press release (NASDAQ:PALI): Q2 GAAP EPS of -$0.12. As of June 30, 2022, the company had cash and cash equivalents of $5M

Seeking Alpha • Jul 27

Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function

Palisade Bio (NASDAQ:PALI) said on Wednesday the first patient had been screened in a Phase 3 study testing its drug, LB1148, to help return bowel function in adult patients undergoing gastrointestinal surgery. The company said it was working to enroll patients and expects to complete enrollment within the next 18-24 months. The drug LB1148 is being developed for administration before the surgeries. The trial is set to enroll about 600 patients and will assess the safety and efficacy of LB1148. The primary endpoint is time to recovery of the upper and lower gastrointestinal tract following surgery. (PALI) rose 1.3% before the bell.

Seeking Alpha • Jun 29

Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy

Palisade Bio (NASDAQ:PALI) is trading 10% higher after it begun Phase 3 study evaluating its drug, LB1148, to help return bowel function in patients undergoing gastrointestinal surgery. The late-stage study will enroll about 600 patients. The primary endpoint of the study is time to recovery of the upper and lower gastrointestinal tract following surgery, which is defined as the time from the end of surgery to the toleration of food and first bowel movement.

Analysis Article • Mar 28

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

	PALI	US Biotechs	US Market
7D	-9.0%	1.0%	1.1%
1Y	166.1%	40.3%	26.7%

Return vs Industry: PALI exceeded the US Biotechs industry which returned 44.4% over the past year.

Return vs Market: PALI exceeded the US Market which returned 25.4% over the past year.

Price Volatility

Is PALI's price volatile compared to industry and market?
PALI volatility
PALI Average Weekly Movement	12.7%
Biotechs Industry Average Movement	10.7%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PALI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PALI's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2001	14	J. Finley	www.palisadebio.com

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.

Palisade Bio, Inc. Fundamentals Summary

How do Palisade Bio's earnings and revenue compare to its market cap?
PALI fundamental statistics
Market cap	US$303.04m
Earnings (TTM)	-US$24.15m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-12.5x

P/E Ratio

Is PALI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PALI income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$24.15m
Earnings	-US$24.15m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.14
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did PALI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/14 09:54
End of Day Share Price	2026/05/14 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Palisade Bio, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
William Wood	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets
Mitchell Kapoor	H.C. Wainwright & Co.

Palisade Bio (PALI) Stock Overview

Risk Analysis

Palisade Bio, Inc. Competitors

SAB Biotherapeutics

Unicycive Therapeutics

Inhibikase Therapeutics

Avalo Therapeutics

Price History & Performance

Recent News & Updates

Palisade Bio Inc Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure And Sustained IC90 Coverage Supporting Once-Daily Dosing In Ulcerative Colitis

Palisade Bio, Inc., Annual General Meeting, Jun 10, 2026

Price target increased by 7.7% to US$11.13

Palisade Bio, Inc. Reports Positive Topline Data From Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

Palisade Bio, Inc. Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 At ECCO 2026

Palisade Bio, Inc. Appoints Bram Verstockt to Clinical Advisory Board

Recent updates

Palisade Bio Inc Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure And Sustained IC90 Coverage Supporting Once-Daily Dosing In Ulcerative Colitis

Palisade Bio, Inc., Annual General Meeting, Jun 10, 2026

Price target increased by 7.7% to US$11.13

Palisade Bio, Inc. Reports Positive Topline Data From Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

Palisade Bio, Inc. Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 At ECCO 2026

Palisade Bio, Inc. Appoints Bram Verstockt to Clinical Advisory Board

Palisade Bio, Inc. Announces Clinical Advisory Board Changes

Palisade Bio, Inc. announced that it expects to receive $0.5 million in funding from Crohn's & Colitis Foundation, Inc.

Palisade Bio, Inc. Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Palisade Bio: Gut Prodrug For IBD With Catalysts

Price target increased by 29% to US$10.33

Palisade Bio, Inc. Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Palisade Bio Announces First Patients Dosed in Phase 1B Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $120 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio, Inc., Annual General Meeting, Oct 17, 2025

Palisade Bio, Inc. Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

New major risk - Financial position

Palisade Bio, Inc. Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, Pali-2108

High number of new and inexperienced directors

New minor risk - Share price stability

Palisade Bio, Inc. Appoints Emil Chuang to Its Board of Directors

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering.

Palisade Bio, Inc. Reports Positive Phase 1A Results for PALI-2108

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio, Inc. Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as A Promising Colon-Specific Pde4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio Receives Notice from the Nasdaq Stock Market

Palisade Bio, Inc. Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

New major risk - Financial position

Palisade Bio, Inc. Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1A/B Study of PALI-2108

Palisade Bio, Inc. Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

High number of new and inexperienced directors

Palisade Bio, Inc. Appoints Brian G. Feagan to its Clinical Advisory Board

Palisade Bio, Inc. Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-To-Severe Ulcerative Colitis Is to Be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Price target increased by 33% to US$45.00

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

New major risk - Financial position

Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108

Price target decreased by 33% to US$22.50

Palisade Bio, Inc. announced that it has received $3.999943 million in funding

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio, Inc. Announces Advisory Board Appointments

New major risk - Share price stability

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Revenue and earnings growth

Price target decreased by 81% to US$3.00

Palisade Bio Receives Non-Compliance Notice from Nasdaq

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.